BM
DRNA

Bridger Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Bridger Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-588,910
Closed -$15.1M – 50
2021
Q1 		$15.1M Buy
+588,910
New +$15M 1.41% 27
2020
Q4 		– Sell
-503,012
Closed -$9.05M – 43
2020
Q3 		$9.05M Sell
503,012
-970,556
-66% -$20.1M 0.72% 32
2020
Q2 		$37.4M Sell
1,473,568
-205,776
-12% -$4.43M 3.47% 12
2020
Q1 		$30.9M Sell
1,679,344
-302,289
-15% -$5.88M 3.57% 15
2019
Q4 		$43.7M Sell
1,981,633
-676,563
-25% -$13.6M 3.15% 16
2019
Q3 		$38.2M Sell
2,658,196
-1,512,869
-36% -$21.6M 3.15% 15
2019
Q2 		$65.7M Sell
4,171,065
-602,653
-13% -$8.19M 5.16% 5
2019
Q1 		$69.9M Hold
4,773,718
– – 5.54% 3
2018
Q4 		$51M Sell
4,773,718
-756,310
-14% -$9.95M 4.25% 7
2018
Q3 		$84.4M Buy
5,530,028
+2,304,501
+71% +$33.5M 4.88% 6
2018
Q2 		$39.5M Buy
3,225,527
+1,998,707
+163% +$25.1M 2.14% 22
2018
Q1 		$11.7M Buy
1,226,820
+320,822
+35% +$3.46M 0.71% 33
2017
Q4 		$8.18M Buy
+905,998
New +$6.67M 0.54% 32

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bridger Management's DRNA Position: Q2 2021 in Review

Bridger Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2021, closing a stake of 588,910 shares — an estimated $15.1M sold.

Bridger Management first reported a position in DRNA in Q4 2017 and held it in 13 quarters. The position peaked at $84.4M in Q3 2018. 203 funds tracked by Wall St. Rank hold DRNA as of Q2 2021.

  • Bridger Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Bridger Management sold 588,910 Dicerna Pharmaceuticals, Inc. shares in Q2 2021, an estimated $15.1M.
  • Bridger Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2017 and held it in 13 quarters.
  • Bridger Management's Dicerna Pharmaceuticals, Inc. position peaked at $84.4M in Q3 2018.
  • 203 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2021.

Based on Bridger Management's 13F filing for Q2 2021, filed 16 Aug 2021.